Drug Trial Radar · NCT06508983
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Jun 14, 2024
Primary completion
Mar 31, 2027
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Hangzhou Sumgen Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.
Conditions
- Relapsed/Refractory Multiple Myeloma
Interventions
SG301 InjectionDrug
Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.
SG301 placeboDrug
Dosage form: solution for infusion Route of administration: intravenous Frequency: weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) thereafter.
pomalidomideDrug
Dosage form: capsule Route of administration: oral Dosage: 4 mg Frequency: once daily on Days 1 through 21 of each 28-day cycle.
dexamethasoneDrug
Dosage form: tablets or solution for infusion Route of administration: oral or intravenous Dosage: 40 mg (participants with BMI \< 18.5 kg/m2 received 20 mg dexamethasone) Frequency: once daily on Day 1, 8, 15, 22 of each 28-day treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (stage 1)Time frame: From date of first dose of study intervention through approximately 30 days after last study intervention administration, assessed up to approximately 4 years.
- Recommended stage 2 dose of SG301 (Stage 1)Time frame: Up to approximately 6 months.
- Progression Free Survival (Stage 2)Time frame: From baseline through the end of study. Assessed every 4 weeks after randomization until C19D1, and every 8 weeks thereafter until disease progression (IMWG criteria) or death whichever occurs first, assessed up to approximately 4 years.
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chaoyang Hospital of Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Guangzhou First People's Hospital
Guangzhou, Guangdong, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Not yet recruiting
First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
The First Affiliated Hospital Of Soochow University
Suzhou, Jiangsu, China · Recruiting
Shanxi Provincial Hospital
Taiyuan, Shanxi, China · Recruiting
The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital)
Xi’an, Shanxi, China · Recruiting
Tianjin Cancer University Airport Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
The Second Affiliated Hospital Zhejiang University School Of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.